Sinopharm Hyundai announced that the company plans to acquire 51% of the shares of Sinopharm Group Guorui Pharmaceutical Co., Ltd. with 406 million yuan in cash. After the acquisition is completed, Guorui Pharmaceutical will become the company's holding subsidiary. This transaction constitutes a related transaction, but it does not constitute a major asset restructuring. It has been reviewed and approved by the 7th meeting of the 9th board of directors of the company, and there is no need to submit it to the shareholders' meeting for review.

Sinopharm Hyundai announced that the company plans to acquire 51% of the shares of Sinopharm Group Guorui Pharmaceutical Co., Ltd. with 406 million yuan in cash. After the acquisition is completed, Guorui Pharmaceutical will become the company's holding subsidiary. This transaction constitutes a related transaction, but it does not constitute a major asset restructuring. It has been reviewed and approved by the 7th meeting of the 9th board of directors of the company, and there is no need to submit it to the shareholders' meeting for review.